The recognition that HR defects reside in a majority of TNBCs, combined with their inherent genomic instability and a lack of targeted therapies, has propelled an interest in testing poly (ADP-ribose) polymerase (PARP) inhibition for this subtype of breast cancer (11, 15). This evidence concerns the gene PARP1 and breast cancer.